1.Clinical differences between primary and secondary premature ovarian failure.
Jung Gu KIM ; Man Chul PARK ; Kyung Hee LEE ; Seok Hyun KIM ; Young Min CHOI ; Chang Jae SHIN ; Shin Yong MOON ; Yoon Seok CHANG ; Jin Yong LEE
Korean Journal of Obstetrics and Gynecology 1991;34(11):1553-1560
No abstract available.
Primary Ovarian Insufficiency*
2.A study on response to treatment and predictability of pregnancy in premature ovarian failure.
Jung Gu KIM ; Man Chul PARK ; Seok Hyun KIM ; Young Min CHOI ; Chang Jae SHIN ; Shin Yong MOON ; Jin Yong LEE ; Yoon Seok CHANG
Korean Journal of Obstetrics and Gynecology 1993;36(7):2208-2213
No abstract available.
Pregnancy*
;
Primary Ovarian Insufficiency*
3.Circulating antibodies directed toward ovarian proteins in women with premature ovarian failure.
Jin Yong LEE ; Jung Gu KIM ; Chang Soo PARK ; Young Min CHOI ; Chang Jae SHIN ; Shin Yong MOON ; Yoon Seok CHANG
Korean Journal of Fertility and Sterility 1993;20(2):137-147
No abstract available.
Antibodies*
;
Female
;
Humans
;
Primary Ovarian Insufficiency*
4.The Analysis of LHbeta -subunit Variants in Infertile Patients with Premature Ovarian Failure (POF) in Korea.
Eu Gene LEE ; Nam Keun KIM ; Sook Hwan LEE ; Jung Jae KO ; Kwang Yul CHA ; Hye Sun JEON ; Kyung Ah LEE
Korean Journal of Fertility and Sterility 2000;27(2):179-182
This study was performed to determine whether the LHbeta -subunit gene missense mutation is present in Korean infertile patients with 46,XX POF women. The variants of LHbeta exon 2 (Trp 8Arg; TGG to CGG and Ile15Thr; ATC ti ACC) were studied in forty-four 46.XX idiopathic POF and 54 nonpregnant women. The LHbeta exon 2 variants were more frequent in POF patients (20.5%) than nonpregnant( 16.7%) women (p>0.05). POF patients with the variant was slightly higher than nonpregnant women with the variant.
Exons
;
Female
;
Humans
;
Korea*
;
Mutation, Missense
;
Primary Ovarian Insufficiency*
5.Molecular variants of the FSH receptor exon 10 (Thr307Ala; A919G) in premature ovarian failure (POF) women by PCR-SSCP.
Nam Keun KIM ; Sook Hwan LEE ; Yoon Sung NAM ; Tae Jong SOHN ; Sang Hee PARK ; Chan PARK ; Jung Jae KO ; Kwang Yul CHA
Korean Journal of Obstetrics and Gynecology 2000;43(7):1144-1146
OBJECTIVE: This study was performed to determine whether the FSH receptor mutation is present in infertile Korean patients with 46,XX premature ovarian failure (POF) women. METHODS: The variant of FSH receptor exon 10 in thirteen 46, XX idiopathic POF and 4 healthy fertile (control) women were studied. Missense mutation in Exon 10 was detected in POF patients and healthy fertile women by polymerase chain reaction-single stranded conformation polymorphism (PCR-SSCP). RESULTS: The variant types of FSH receptor exon 10 (Thr307Ala; A919G) were found in healthy fertile (control) and POF women. CONCLUSIONS: This mutation may not be specific in POF patients and further study is needed in fertile (control) and POF women.
Exons*
;
Female
;
Humans
;
Mutation, Missense
;
Primary Ovarian Insufficiency*
;
Receptors, FSH*
7.Consequences of chemotherapeutic agents on primordial follicles and future clinical applications
So Youn KIM ; Geum Joon CHO ; John S DAVIS
Obstetrics & Gynecology Science 2019;62(6):382-390
The ovarian reserve is necessary for female fertility and endocrine health. Commonly used cancer therapies diminish the ovarian reserve, thus, resulting in primary ovarian insufficiency, which clinically presents as infertility and endocrine dysfunction. Prepubertal children who have undergone cancer therapies often experience delayed puberty or cannot initiate puberty and require endocrine support to maintain a normal life. Thus, developing an effective intervention to prevent loss of the ovarian reserve is an unmet need for these cancer patients. The selection of adjuvant therapies to protect the ovarian reserve against cancer therapies underlies the mechanism of loss of primordial follicles (PFs). Several theories have been proposed to explain the loss of PFs. The “burn out” theory postulates that chemotherapeutic agents activate dormant PFs through an activation pathway. Another theory posits that chemotherapeutic agents destroy PFs through an “apoptotic pathway” due to high sensitivity to DNA damage. However, the mechanisms causing loss of the ovarian reserve remains largely speculative. Here, we review current literature in this area and consider the mechanisms of how gonadotoxic therapies deplete PFs in the ovarian reserve.
Adolescent
;
Child
;
DNA Damage
;
Female
;
Fertility
;
Fertility Preservation
;
Humans
;
Infertility
;
Ovarian Follicle
;
Ovarian Reserve
;
Primary Ovarian Insufficiency
;
Puberty
;
Puberty, Delayed
8.Primordial follicle activation as new treatment for primary ovarian insufficiency
Clinical and Experimental Reproductive Medicine 2019;46(2):43-49
Primordial follicle activation is a process in which individual primordial follicles leave their dormant state and enter a growth phase. While existing hormone stimulation strategies targeted the growing follicles, the remaining dormant primordial follicles were ruled out from clinical use. Recently, in vitro activation (IVA), which is a method for controlling primordial follicle activation, has provided an innovative technology for primary ovarian insufficiency (POI) patients. IVA was developed based on Hippo signaling and phosphatase and tensin homolog (PTEN)/phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT)/forkhead box O3 (FOXO3) signaling modulation. With this method, dormant primordial follicles are activated to enter growth phase and developed into competent oocytes. IVA has been successfully applied in POI patients who only have a few remaining remnant primordial follicles in the ovary, and healthy pregnancies and deliveries have been reported. IVA may also provide a promising option for fertility preservation in cancer patients and prepubertal girls whose fertility preservation choices are limited to tissue cryopreservation. Here, we review the basic mechanisms, translational studies, and current clinical results for IVA. Limitations and further study requirements that could potentially optimize IVA for future use will also be discussed.
Cryopreservation
;
Female
;
Fertility Preservation
;
Humans
;
In Vitro Techniques
;
Methods
;
Oocytes
;
Ovarian Follicle
;
Ovary
;
Phosphotransferases
;
Pregnancy
;
Primary Ovarian Insufficiency
9.Ovarian tissue cryopreservation and transplantation.
Ki Hyun PARK ; Byung Seok LEE ; Da Jung CHUNG
Korean Journal of Obstetrics and Gynecology 2006;49(12):2473-2478
This review focuses on the current options for fertility preservation in patients with high risk of premature ovarian failure. Available cryopreservation options include embryo cryopreservation, oocyte cryopreservation, and ovarian tissue cryopreservation. Ovarian tissue cryopreservation and transplantation has been tried for some time in animals, but only recently successful pregnancy and livebirth in human has been reported. Options of developing follicles and restoring fertility after ovarian tissue cryopreservation are autotransplantation, xenotransplantation, and tissue culture. This review discusses the merits and faults of each option and future directions for developing and standardizing the ovarian tissue cryopreservation and transplantation procedure, systemically covering previously published data.
Animals
;
Autografts
;
Cryopreservation*
;
Embryonic Structures
;
Fertility
;
Fertility Preservation
;
Humans
;
Oocytes
;
Pregnancy
;
Primary Ovarian Insufficiency
;
Transplantation, Heterologous
10.A Case of Premature Ovarian Failure Assosiated with Gonadal Dysgenesis.
Sook Hwan LEE ; Tae Ki YOON ; Kwang Yul CHA ; Yoon Sung NAM ; In Pyung KWAK
Korean Journal of Obstetrics and Gynecology 1999;42(1):138-141
Prenature ovarian failure is a condition causing amenarrhea, hypoestrogenism, and elevated genadotropins in women younger than 40 years. A karyotype should be performed as part of basic laboratory evaluation for all patients with premature ovarian failure and prodromal premature ovarian failure. Development of a malignancy in a dysgenetic gonad is of major concern. The presence of a fragment of the Y chromosome is thought to be a key to the oncogenic potential of these gonads. The search for the testicular determining factor(TDF) has engendered much confusion about which part of the Y chromosome plays a role in malignancy. This was initially postulated to be the H- Y antigen. More recent data, however, localize the area near the centromere of the Y Chromosome, on the long arm(Yq). Malignant potential is clearly not linked to the testicular determining factor itself(SRY). This is a critical point in clinical medicine. Feilure to display SRY or a closely related sequence does not rule out the presence of the segment of the Y chromosome postulated to be associated with the development of malignancies. We have experienced a case of premature ovarian failure with chtomosomal abnormality involving Y chromosome fragment. So we report this case with a brief review of literatures.
Centromere
;
Clinical Medicine
;
Female
;
Gonadal Dysgenesis*
;
Gonads*
;
Humans
;
Karyotype
;
Primary Ovarian Insufficiency*
;
Y Chromosome